Corneal lipidosis is the buildup of fats and cholesterol within the normally transparent cornea, gradually turning it cloudy and impairing vision. The condition is not a single disease but an umbrella term covering several distinct patterns of lipid accumulation, from inherited genetic disorders to secondary deposits triggered by blood vessel growth or elevated blood cholesterol. Because the cornea depends on its crystal-clear structure to focus light, even small lipid deposits can scatter incoming rays and cause glare, haziness, or progressive loss of visual sharpness.
How Lipids Get Into the Cornea
A healthy cornea has no blood vessels. It gets its oxygen and nutrients from tears on the outside and the fluid behind it (the aqueous humor). That lack of blood supply is actually what keeps it transparent. Problems start when new blood vessels grow into the cornea, a process called neovascularization, usually in response to injury, infection, or chronic inflammation. These newly formed vessels are structurally immature: they lack the normal tight barriers that keep large molecules inside the bloodstream. Lipoproteins, the cholesterol-carrying particles in blood, leak through these leaky vessel walls and seep into the corneal tissue.
Once lipid reaches the corneal stroma (the thick middle layer that makes up most of the cornea’s structure), local cells called fibroblasts try to clean it up. They engulf the cholesterol-rich material, break it down internally, and either use it or store it as droplets. But there is a limit. When these cells become overloaded, they die, releasing their stored lipid and forming crystalline deposits and waxy sheets of cholesterol throughout the stroma. The result is a visible, yellowish-white opacity that can grow over months or years.
High levels of circulating cholesterol make this process worse. The more lipid flowing through the blood, the more leaks through any abnormal corneal vessels. Early researchers proposed that most patients with lipid keratopathy also had elevated serum cholesterol, and though that link is not absolute, it remains an important contributing factor.
Primary Versus Secondary Forms
Corneal lipidosis is broadly classified into two categories. Secondary lipid keratopathy is by far the more common. It arises when some other condition causes corneal blood vessels to form first, and lipid deposition follows. Herpes simplex or herpes zoster infections are classic triggers: the chronic inflammation and scarring they leave behind encourage new vessel growth, which then becomes the pathway for lipid leakage. Other causes include chemical burns, prior corneal surgery, and long-standing contact-lens-related injury. A published case of a 62-year-old man with herpes zoster keratitis illustrates the pattern well: he developed painless progressive vision loss and corneal scarring complicated by lipid deposits.
Primary lipid keratopathy, by contrast, occurs without any preceding corneal disease or obvious neovascularization. It is rarer and more puzzling. In some primary cases, elevated blood lipids are the apparent driver. In others, an inherited defect in how the cornea handles cholesterol is responsible, as in Schnyder corneal dystrophy. The distinction between primary and secondary matters because treatment strategies differ: secondary cases often focus on eliminating the underlying vascular trigger, while primary cases may require addressing systemic lipid levels or, in genetic forms, surgical intervention.
Schnyder Corneal Dystrophy and the Genetic Side
Schnyder corneal dystrophy is the best-understood genetic cause of corneal lipidosis. It is a rare inherited condition in which cholesterol accumulates in the cornea over a lifetime, typically becoming noticeable in the second or third decade of life. The hallmark finding is a ring or disc of crystalline deposits in the central cornea, though not every patient develops visible crystals. Some show only a diffuse haziness.
The genetic culprit is a mutation in a gene called UBIAD1, which encodes a protein involved in cholesterol metabolism within cells. Researchers identified UBIAD1 mutations as the cause of Schnyder dystrophy and noted that the protein may play a role in intracellular cholesterol regulation, possibly by interacting with apolipoprotein E, a component of the particles that carry cholesterol through the bloodstream. The protein also appears to bind to an enzyme central to cholesterol production (HMG-CoA reductase), and mutations stabilize that enzyme in a way that ramps up cholesterol synthesis. The net effect is that corneal cells overproduce and accumulate cholesterol locally, even when blood cholesterol levels are normal, though many patients with Schnyder dystrophy do also have elevated systemic cholesterol.
Chemical analysis of corneas affected by Schnyder dystrophy confirms just how dramatic the lipid buildup is. One study found that unesterified cholesterol in affected corneas was roughly thirteen times higher than in normal control corneas, and phospholipid levels were about six times higher. Sphingomyelin was the dominant phospholipid in the affected tissue. These findings underscore that the problem is not just a thin film of fat on the surface but a deep, chemical restructuring of the corneal stroma.
Systemic Conditions That Drive Corneal Lipid Deposits
Outside of genetic dystrophies, several systemic health problems can set the stage for corneal lipidosis. The most straightforward connection is with hypercholesterolemia. Chronically elevated blood cholesterol promotes lipid deposition throughout the body, including the corneas, tendons, and arteries. In the cornea, this can manifest as arcus lipoides (the grayish-white ring often seen at the edge of the cornea in older adults) or, when more severe, as diffuse stromal opacification.
Thyroid disease is another important systemic link, particularly in veterinary medicine. Hypothyroidism slows metabolism and frequently leads to elevated blood lipids. A documented case of a dog with hypothyroidism showed severe bilateral arcus lipoides corneae along with hyperlipidemia presumed to result from the thyroid condition. Treating the underlying thyroid dysfunction and surgically removing the corneal deposits improved the dog’s corneal clarity. Hyperadrenocorticism (overproduction of cortisol, sometimes called Cushing’s disease) is yet another systemic condition associated with corneal lipid and calcium deposition, as reported in a case involving a seven-year-old Poodle that developed bilateral corneal degeneration.
These systemic links matter because corneal lipidosis is sometimes the first visible sign of an underlying metabolic problem. An eye exam that reveals unexpected lipid deposits in a younger person, or in an animal, can prompt blood work that uncovers high cholesterol, thyroid dysfunction, or another treatable condition.
What Corneal Lipidosis Looks and Feels Like
The deposits themselves are usually white, yellow-white, or cream-colored opacities within the cornea. They can range from a faint haze visible only under a slit lamp to dense, opaque plaques obvious to the naked eye. In Schnyder dystrophy, refractile crystals may be visible, giving the cornea a sparkling or frosted-glass appearance. In secondary lipid keratopathy, the opacity tends to cluster around areas of blood vessel growth, often with a fan-shaped or wedge-shaped pattern radiating from the vessels into the central cornea.
The most common symptom patients notice is glare. Light hitting the cholesterol deposits scatters rather than passing cleanly through, creating a washed-out, hazy quality to vision that is especially bothersome in bright conditions or when driving at night. Patients with Schnyder dystrophy often complain of glare before their measured visual acuity drops significantly, because scattered light degrades contrast sensitivity even when the eye can still read a standard letter chart. As the condition progresses, visual acuity itself declines, sometimes to the point where daily activities become difficult.
Pain is uncommon unless the cornea’s surface breaks down or an underlying infection flares up. Many patients with primary or slowly progressive lipid keratopathy describe a gradual, painless blurring that they initially attribute to aging or a need for new glasses.
Diagnosis and Imaging
Slit-lamp examination remains the first-line diagnostic tool. An experienced examiner can often distinguish lipid deposits from other types of corneal opacity based on color, location, and the pattern of any associated blood vessels. But modern imaging adds valuable detail. Optical coherence tomography (OCT) can reveal the depth and distribution of deposits within the corneal layers, and confocal microscopy can identify individual crystalline structures at the cellular level. In patients with Schnyder dystrophy, OCT and confocal imaging have confirmed that crystalline deposits concentrate mainly in the front portion of the stroma, extending from just beneath the surface epithelium to a depth of roughly 80 to 150 micrometers.
Histopathology, when tissue is available (for example, after a corneal transplant), provides definitive confirmation. Special stains like oil red O highlight lipid deposits, and fluorescent probes such as filipin can specifically detect unesterified cholesterol, confirming the chemical identity of the material.
One diagnostic challenge is separating lipid keratopathy from conditions that can look similar under the slit lamp. Corneal arcus, a common and usually harmless lipid ring at the corneal periphery, can occasionally be confused with early lipid keratopathy, especially in younger patients where arcus is unexpected. Other conditions in the differential include calcium-based deposits (band keratopathy), infectious crystalline keratopathy, and certain drug-induced corneal deposits. The clinical history, the pattern of the opacity, and the presence or absence of blood vessels usually allow a clear distinction, but histopathology or genetic testing may be needed in ambiguous cases.
Treatment Approaches
Treatment depends on the type and severity of the lipid deposits. For secondary lipid keratopathy driven by corneal blood vessels, the first goal is to shut down those vessels. Anti-vascular endothelial growth factor (anti-VEGF) injections, either into the eye or applied topically, can reduce neovascularization. Argon laser photocoagulation of the feeding vessels has also been used to cut off the lipid supply. These vascular treatments do not remove deposits already in place, but they can slow or halt further accumulation.
When lipid deposits are dense enough to significantly impair vision, surgical options come into play. Lamellar keratectomy, in which the surgeon removes the superficial layers of the cornea containing the deposits, can restore clarity. This approach was used successfully in the hypothyroid dog mentioned earlier, with documented improvement in corneal transparency after surgery. For deeper or more widespread deposits, a full-thickness corneal transplant (penetrating keratoplasty) may be necessary. This is the standard intervention for advanced Schnyder dystrophy when vision loss becomes severe. The risk, however, is that lipid deposits can recur in the transplanted tissue, particularly if the underlying metabolic or genetic driver persists.
Addressing systemic factors is equally important. If blood cholesterol is elevated, lipid-lowering therapy with statins or dietary modification may reduce the supply of lipid reaching the cornea. In cases linked to thyroid disease or adrenal dysfunction, treating the hormonal disorder can improve the metabolic environment and sometimes slow corneal changes. There is no single drug that directly dissolves corneal lipid deposits once they have formed, so prevention and early intervention remain the most effective strategies.
Why This Happens in Animals Too
Corneal lipidosis is not exclusively a human condition. Dogs are particularly prone to it, and the veterinary literature has described the condition in detail. Breeds with a predisposition to hyperlipidemia, including Cavalier King Charles Spaniels and Shetland Sheepdogs, develop corneal lipid deposits more frequently. The underlying mechanisms mirror what happens in humans: elevated blood lipids, corneal vascular changes, or both conspire to deposit cholesterol in the stroma.
Animal models have also been deliberately created to study the condition. Rabbits fed a high-cholesterol diet and subjected to corneal suture placement (to induce neovascularization) develop lipid keratopathy that closely resembles the human secondary form, making them useful for testing potential treatments. Separate research on cholesterol-fed rabbits has shown progressive cholesterol deposition in the cornea, conjunctiva, tendons, and arteries, illustrating how systemic lipid excess affects multiple tissues simultaneously.
For pet owners, the practical takeaway is that a cloudy or whitish spot in a dog’s eye warrants veterinary attention. It may be a benign age-related change, but it can also signal an underlying metabolic disorder like hypothyroidism or Cushing’s disease that benefits from treatment.
Lipid Disorders and the Broader Eye
Corneal lipidosis does not exist in isolation. Disordered lipid metabolism affects other parts of the eye as well. The same metabolic imbalances that deposit cholesterol in the cornea are closely associated with the development and progression of cataracts, glaucoma, age-related macular degeneration, and diabetic retinopathy. This means a patient diagnosed with corneal lipid deposits may be at heightened risk for other sight-threatening conditions, and comprehensive eye screening is warranted beyond just examining the cornea.
The relationship also runs in the other direction. An ophthalmologist who notices unexpected corneal lipid deposits in a young or middle-aged patient may be the first clinician to suspect a systemic lipid disorder. Arcus lipoides appearing before age 40, for instance, has long been considered a red flag for familial hypercholesterolemia. In that sense, the cornea serves as a window not only into the eye’s health but into the body’s metabolic state, making corneal lipidosis a finding with implications that reach well beyond the surface of the eye.